This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies. You can learn more about our use of cookies and similar technologies and your choices by reviewing our Privacy Policy. By clicking “I agree” you agree to our use of cookies and similar technologies.
The Peptide Moment: How FDA’s Regulatory Reversal Creates Risk and Opportunity for Venture Capital and Private Equity
A Regulatory Shift That Demands Attention
The New York Times reported on March 31, 2026 that the U.S. Food and Drug Administration is moving to lift its ban on more than a dozen injectable peptides that were restricted in 2023 over significant safety concerns. The announcement follows months of public advocacy by Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., who made headlines on Joe Rogan’s podcast declaring himself a fan of peptides and promising to end what he called the FDA’s war on the compounds. The regulatory reversal is expected to move roughly 14 peptides, including BPC-157, ipamorelin, Thymosin Alpha-1, TB-500, Selank, Semax, and GHK-Cu, from Category 2 (restricted) back to Category 1, where licensed compounding pharmacies can prepare them under physician prescription.
The market has already reacted. Search interest in peptides recently surpassed searches for Ozempic. Shares of Hims & Hers surged on the news. Consumer health companies are racing to launch peptide offerings. And venture capital and private equity firms with exposure to wellness platforms, telehealth companies, med spas, compounding pharmacies, and supplement businesses are suddenly navigating a landscape that looks very different from the one they underwrote.
But the regulatory picture is more complicated than the headlines suggest. FDA’s senior scientific leadership reportedly retains serious reservations about these compounds. The compounds being reconsidered have not completed the rigorous human clinical trials required for full FDA approval. Safety concerns around immunogenicity, organ toxicity, and product impurity drove the original 2023 ban, and those concerns have not been resolved by any new clinical data. What has changed is the political environment at HHS, not the science. For venture capital and private equity firms and their portfolio companies, that distinction matters enormously.
The Compliance Landscape Is Not Resolved. It Is Shifting.
A regulatory reversal of this kind does not eliminate compliance risk. It transforms it. Companies that have operated in the gray market or in technical noncompliance with the 2023 restrictions face lookback exposure. Companies now racing to market must build quality, labeling, advertising, and prescription-management infrastructure that can survive scrutiny in a still-unsettled environment. And any company that treats this moment as a green light to move fast without building proper compliance architecture is taking on significant legal, regulatory, and reputational risk.
Product quality and supply chain integrity remain central concerns. The 2023 regulatory restrictions drove significant peptide demand into gray markets and overseas sources. A 2024 analysis of gray market peptide products found substantial variability between actual peptide content and label claims, bacterial endotoxin contamination, and, in some cases, entirely incorrect compounds.
Companies acquired or invested in during this period may have supply chain practices that do not conform to FDA requirements, including USP 797/795 compounding standards and FDA registered API sourcing. Key questions include whether products were prepared by licensed pharmacists in state licensed pharmacies (503A) or in registered outsourcing facilities under appropriate supervision (503B), and whether companies that previously marketed products as “research chemicals” have a viable path to lawful 503B production.
If companies that historically operated in regulatory gray areas continue to do so without conforming to newly defined legal standards, they materially increase their exposure to civil and criminal enforcement. An industry that previously benefited from regulatory ambiguity may now face heightened scrutiny once clear and enforceable guidelines are established, making noncompliance more readily identifiable and more easily pursued by both regulatory agencies and law enforcement.
Validating the quality, compliance, and enforcement risk profile of portfolio companies in this space is not a formality; it is a core diligence requirement.
Prescription and prescribing practice compliance pose additional risk. Compounded peptides require a valid physician prescription. Telehealth platforms that facilitated peptide prescribing without adequate clinical evaluation protocols, that used offshore prescribers, or that structured their business to generate high-volume prescriptions without individualized patient assessment, have built practices that resemble the GLP-1 compounding enforcement actions the FDA has already pursued. The agency’s warning letter to MEDVi in February 2026, just weeks before the peptide reversal was announced, is a useful data point. Regulatory reversals do not immunize companies for prior conduct.
Finally, there is the question of what the post-reversal regulatory environment will actually look like in practice. The formal FDA publication updating the Category 1 list had not been released as of April 6, 2026. Until the updated list is formally published, compounding pharmacies technically remain unable to compound the affected peptides. Companies that move to market before the formal publication drop are taking on regulatory timing risk that their investors may not fully appreciate.
What Venture Capital and Private Equity Need Before Writing the Check
The combination of regulatory uncertainty, a history of gray-market operation, and an aggressive race to market creates a profile that requires specialized due diligence. Standard commercial diligence is not designed to evaluate FDA regulatory risk in this environment. Venture capital and private equity firms looking at peptide platforms, wellness companies, compounding pharmacies, or telehealth operators need advisors who understand the regulatory architecture, can identify historical compliance gaps, and can assess the buildability of a compliant operation post-close.
Guidepost Solutions has developed a dedicated FDA Regulatory Risk practice for exactly this kind of situation. Our team works with venture capital funds and private equity firms and their portfolio companies to conduct the investigative and compliance work that commercial diligence does not reach.
Specialized Support for FDA/DEA Regulatory Risk
Pre-Close Regulatory Risk Assessment
Before closing a transaction involving a peptide company, wellness platform, compounding pharmacy, or telehealth operator, our team can conduct a structured regulatory risk assessment covering the target’s peptide sourcing and supply chain practices, advertising and claims history, prescribing model and prescription management infrastructure, prior FDA and FTC interactions, and state pharmacy board compliance. This type of investigative and compliance assessment is designed to give the deal team a clear picture of what they are acquiring and what remediation will be required post-close.
FDA Regulatory Compliance Program Design
For companies that have been operating in a gray-market or technically noncompliant mode, the regulatory reversal represents an opportunity to come into compliance in a structured way. We recommend designing and implementing FDA-aligned compliance programs covering supply chain qualification, labeling and advertising review processes, prescribing protocols, and quality management systems. Our team draws on former federal prosecutors, criminal investigators, and regulatory experts who understand how FDA enforcement decisions are made and what a defensible compliance posture looks like.
Portfolio Company Monitoring
In complex or high-risk transactions, venture capital funds and private equity sponsors increasingly require ongoing monitoring of portfolio company compliance as a condition of deal structure or as a post-close governance requirement. Engaging with an expert who has extensive experience serving as an independent compliance monitor across regulated industries, providing periodic assessments, flag reporting, and remediation support can be a huge benefit. In the peptide and wellness context, where the regulatory environment is actively evolving, ongoing monitoring provides sponsors with real-time visibility into compliance posture and early warning of emerging risks.
Investigations and Remediation
When historical compliance issues surface after close, whether through government inquiry, whistleblower activity, or internal discovery, our investigations team provides the independent, privileged investigation infrastructure needed to assess scope, contain risk, and engage with regulators. Our team’s background includes former SDNY prosecutors, FDA- OCI special agents, DEA agents, investigators and executives, and FDA regulatory experts who can navigate both the investigative and regulatory dimensions of a problem simultaneously.
DEA Regulatory Compliance
Peptide companies that also operate in the broader pharmaceutical or controlled substance space may face overlapping DEA registration and diversion compliance requirements. Guidepost’s DEA Regulatory Compliance Practice, led by former senior DEA executives, works with compounders, distributors, and health systems on the full range of DEA registration, diversion prevention, and compliance audit services.
The Opportunity Window Is Real. So Is the Risk Window.
The FDA’s expected reversal on peptides is a genuine market development. The wellness and longevity space is large, growing, and increasingly attractive to institutional capital. Hims & Hers, Superpower, and a range of telehealth and wellness platforms are already positioning to capture the post-reversal market. Venture capital and private equity firms with existing portfolio exposure or active investment theses in this space are right to view this moment as significant.
But the firms that will generate durable returns in this space are the ones that treat compliance infrastructure as a value driver, not a drag. A platform that can demonstrate to regulators, acquirers, and future investors that it built its peptide business on sound regulatory foundations is a fundamentally more valuable asset than one that raced to market and accumulated liability.
Guidepost Solutions partners with venture capital funds, private equity sponsors and their portfolio companies to build that foundation. Our team brings the investigative depth, regulatory knowledge, and compliance execution capability to help sponsors evaluate risk before close, remediate legacy issues post-close, and build the monitoring infrastructure that protects long-term value.
MSU Institutional Assessment + RAMAGELLAN MonitorshipEmpire/Liberty Review